Dr Ramin Alipour
Clinical (Fellow)
The Sir Peter MacCallum Department of Oncology
68 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT
DOI: 10.2967/jnumed.125.2719952026
Journal article
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
DOI: 10.1016/S1470-2045(26)00120-82026
Journal article
Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy
DOI: 10.2967/JNUMED.126.2725312026
Journal article
Real world outcomes of neoadjuvant immune checkpoint blockade (ICB) for resectable stage III melanoma: Pathologic response and FDG PET/CT correlates.
DOI: 10.1200/jco.2026.44.16_suppl.95692026
Journal article
Fully automated deep learning-based algorithm for contouring primary malignancy on PSMA PET/CT: results from the proPSMA trial in men with intermediate to high-risk prostate cancer
DOI: 10.1016/j.eanmj.2026.1002192026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-32026
Journal article
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer
DOI: 10.1148/radiol.252672
RECENT SCHOLARLY WORKS
2026
Journal article
A Practical Guide to Somatostatin Receptor Imaging with PET/Computed Tomography
DOI: 10.1016/j.rcl.2026.07.0032025
Journal article
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
DOI: 10.2967/jnumed.125.2708042025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-5